|
Homologous recombination deficiency (HRD) in patients with pancreatic cancer (PC) and response to chemotherapy. |
|
|
Consulting or Advisory Role - Merrimack |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Myriad Genetics |
Stock and Other Ownership Interests - Myriad Genetics |
|
|
Consulting or Advisory Role - Amgen; Bayer; Genentech/Roche; Lilly/ImClone |
|
Travel, Accommodations, Expenses - Merck KGaA |